questionsmedicales.fr
Actions chimiques et utilisations
Actions pharmacologiques
Mécanismes moléculaires de l'action pharmacologique
Antienzymes
Antienzymes : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Inhibiteurs enzymatiques
Tests de laboratoire
Symptômes
Troubles digestifs
Tests diagnostiques
Anticorps
Imagerie médicale
Évaluation des organes
Marqueurs biochimiques
Enzymes
Symptômes
5
Symptômes
Troubles métaboliques
Douleur
Troubles digestifs
Enzymes
Symptômes spécifiques
Asymptomatique
Inhibition enzymatique
Évolution des symptômes
Traitement
Prévention
5
Prévention
Alimentation équilibrée
Contrôles médicaux
Détection précoce
Éducation médicale
Médicaments
Traitements
5
Chimiothérapie
Anticancéreux
Administration de médicaments
Voies d'administration
Effets secondaires
Nausées
Médecine personnalisée
Inhibition enzymatique
Complications
5
Complications
Troubles métaboliques
Maladies chroniques
Diabète
Surdosage
Effets indésirables
Gestion des complications
Suivi médical
Facteurs de risque
5
Facteurs de risque
Antécédents familiaux
Âge
Dégradation enzymatique
Maladies auto-immunes
Inhibition enzymatique
Médicaments
Interférence enzymatique
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Antienzymes : Questions médicales les plus fréquentes",
"headline": "Antienzymes : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Antienzymes : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-26",
"dateModified": "2025-04-22",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Antienzymes"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Mécanismes moléculaires de l'action pharmacologique",
"url": "https://questionsmedicales.fr/mesh/D045504",
"about": {
"@type": "MedicalCondition",
"name": "Mécanismes moléculaires de l'action pharmacologique",
"code": {
"@type": "MedicalCode",
"code": "D045504",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs des protéines activatrices de la 5-lipoxygénase",
"alternateName": "5-Lipoxygenase-Activating Protein Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D058946",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des protéines activatrices de la 5-lipoxygénase",
"code": {
"@type": "MedicalCode",
"code": "D058946",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.086"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de l'acétaldéhyde déshydrogénase",
"alternateName": "Acetaldehyde Dehydrogenase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065086",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de l'acétaldéhyde déshydrogénase",
"code": {
"@type": "MedicalCode",
"code": "D065086",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.089"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de l'adénosine désaminase",
"alternateName": "Adenosine Deaminase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D058892",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de l'adénosine désaminase",
"code": {
"@type": "MedicalCode",
"code": "D058892",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.092"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs des adénylate cyclases",
"alternateName": "Adenylyl Cyclase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D000067956",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des adénylate cyclases",
"code": {
"@type": "MedicalCode",
"code": "D000067956",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.108"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la calcineurine",
"alternateName": "Calcineurin Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065095",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la calcineurine",
"code": {
"@type": "MedicalCode",
"code": "D065095",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.174"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de l'anhydrase carbonique",
"alternateName": "Carbonic Anhydrase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D002257",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de l'anhydrase carbonique",
"code": {
"@type": "MedicalCode",
"code": "D002257",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.200"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs et modulateurs de la gamma-secrétase",
"alternateName": "Gamma Secretase Inhibitors and Modulators",
"url": "https://questionsmedicales.fr/mesh/D000091062",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs et modulateurs de la gamma-secrétase",
"code": {
"@type": "MedicalCode",
"code": "D000091062",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.315"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs des enzymes du cytochrome P-450",
"alternateName": "Cytochrome P-450 Enzyme Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065607",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des enzymes du cytochrome P-450",
"code": {
"@type": "MedicalCode",
"code": "D065607",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.335"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs du cytochrome P-450 CYP1A2",
"alternateName": "Cytochrome P-450 CYP1A2 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065609",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs du cytochrome P-450 CYP1A2",
"code": {
"@type": "MedicalCode",
"code": "D065609",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.335.120"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs du cytochrome P-450 CYP2B6",
"alternateName": "Cytochrome P-450 CYP2B6 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065686",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs du cytochrome P-450 CYP2B6",
"code": {
"@type": "MedicalCode",
"code": "D065686",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.335.260"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs du cytochrome P-450 CYP2C8",
"alternateName": "Cytochrome P-450 CYP2C8 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065687",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs du cytochrome P-450 CYP2C8",
"code": {
"@type": "MedicalCode",
"code": "D065687",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.335.308"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs du cytochrome P-450 CYP2C19",
"alternateName": "Cytochrome P-450 CYP2C19 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065689",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs du cytochrome P-450 CYP2C19",
"code": {
"@type": "MedicalCode",
"code": "D065689",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.335.319"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs du cytochrome P-450 CYP2C9",
"alternateName": "Cytochrome P-450 CYP2C9 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065688",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs du cytochrome P-450 CYP2C9",
"code": {
"@type": "MedicalCode",
"code": "D065688",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.335.329"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs du cytochrome P-450 CYP2D6",
"alternateName": "Cytochrome P-450 CYP2D6 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065690",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs du cytochrome P-450 CYP2D6",
"code": {
"@type": "MedicalCode",
"code": "D065690",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.335.368"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs du cytochrome P-450 CYP2E1",
"alternateName": "Cytochrome P-450 CYP2E1 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065691",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs du cytochrome P-450 CYP2E1",
"code": {
"@type": "MedicalCode",
"code": "D065691",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.335.421"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs du cytochrome P-450 CYP3A",
"alternateName": "Cytochrome P-450 CYP3A Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065692",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs du cytochrome P-450 CYP3A",
"code": {
"@type": "MedicalCode",
"code": "D065692",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.335.503"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Antifoliques",
"alternateName": "Folic Acid Antagonists",
"url": "https://questionsmedicales.fr/mesh/D005493",
"about": {
"@type": "MedicalCondition",
"name": "Antifoliques",
"code": {
"@type": "MedicalCode",
"code": "D005493",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.350"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de désacétylase d'histone",
"alternateName": "Histone Deacetylase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D056572",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de désacétylase d'histone",
"code": {
"@type": "MedicalCode",
"code": "D056572",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.360"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de l'intégrase",
"alternateName": "Integrase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D019429",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de l'intégrase",
"code": {
"@type": "MedicalCode",
"code": "D019429",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.375"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la lipoxygénase",
"alternateName": "Lipoxygenase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D016859",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la lipoxygénase",
"code": {
"@type": "MedicalCode",
"code": "D016859",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.480"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la monoamine oxydase",
"alternateName": "Monoamine Oxidase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D008996",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la monoamine oxydase",
"code": {
"@type": "MedicalCode",
"code": "D008996",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.616"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la synthèse d'acide nucléique",
"alternateName": "Nucleic Acid Synthesis Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D019384",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la synthèse d'acide nucléique",
"code": {
"@type": "MedicalCode",
"code": "D019384",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.675"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de l'ornithine décarboxylase",
"alternateName": "Ornithine Decarboxylase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065108",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de l'ornithine décarboxylase",
"code": {
"@type": "MedicalCode",
"code": "D065108",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.705"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la phosphodiestérase",
"alternateName": "Phosphodiesterase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D010726",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la phosphodiestérase",
"code": {
"@type": "MedicalCode",
"code": "D010726",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.735"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la phosphodiestérase-3",
"alternateName": "Phosphodiesterase 3 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D058987",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la phosphodiestérase-3",
"code": {
"@type": "MedicalCode",
"code": "D058987",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.735.249"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la phosphodiestérase-4",
"alternateName": "Phosphodiesterase 4 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D058988",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la phosphodiestérase-4",
"code": {
"@type": "MedicalCode",
"code": "D058988",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.735.374"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la phosphodiestérase-5",
"alternateName": "Phosphodiesterase 5 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D058986",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la phosphodiestérase-5",
"code": {
"@type": "MedicalCode",
"code": "D058986",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.735.500"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs des phosphoinositide-3 kinases",
"alternateName": "Phosphoinositide-3 Kinase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D000081082",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des phosphoinositide-3 kinases",
"code": {
"@type": "MedicalCode",
"code": "D000081082",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.736"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la phospholipase A2",
"alternateName": "Phospholipase A2 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D064801",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la phospholipase A2",
"code": {
"@type": "MedicalCode",
"code": "D064801",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.737"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de prolyle hydroxylases",
"alternateName": "Prolyl-Hydroxylase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D064800",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de prolyle hydroxylases",
"code": {
"@type": "MedicalCode",
"code": "D064800",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.740"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de protéases",
"alternateName": "Protease Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D011480",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de protéases",
"code": {
"@type": "MedicalCode",
"code": "D011480",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de l'enzyme de conversion de l'angiotensine",
"alternateName": "Angiotensin-Converting Enzyme Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D000806",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de l'enzyme de conversion de l'angiotensine",
"code": {
"@type": "MedicalCode",
"code": "D000806",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.085"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs des vasopeptidases",
"alternateName": "Vasopeptidase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D000075563",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des vasopeptidases",
"code": {
"@type": "MedicalCode",
"code": "D000075563",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.085.500"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs des vasopeptidases",
"alternateName": "Vasopeptidase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D000075563",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des vasopeptidases",
"code": {
"@type": "MedicalCode",
"code": "D000075563",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.085.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la cystéine protéinase",
"alternateName": "Cysteine Proteinase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D015853",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la cystéine protéinase",
"code": {
"@type": "MedicalCode",
"code": "D015853",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.325"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs des caspases",
"alternateName": "Caspase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D061945",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des caspases",
"code": {
"@type": "MedicalCode",
"code": "D061945",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.325.500"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs des caspases",
"alternateName": "Caspase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D061945",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des caspases",
"code": {
"@type": "MedicalCode",
"code": "D061945",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.325.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de métalloprotéinases matricielles",
"alternateName": "Matrix Metalloproteinase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D061965",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de métalloprotéinases matricielles",
"code": {
"@type": "MedicalCode",
"code": "D061965",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.610"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs du protéasome",
"alternateName": "Proteasome Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D061988",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs du protéasome",
"code": {
"@type": "MedicalCode",
"code": "D061988",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.705"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la rénine",
"alternateName": "Renin Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D000092502",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la rénine",
"code": {
"@type": "MedicalCode",
"code": "D000092502",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.753"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la sérine protéinase",
"alternateName": "Serine Proteinase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D015842",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la sérine protéinase",
"code": {
"@type": "MedicalCode",
"code": "D015842",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.800"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de serine peptidase de type Kazal",
"alternateName": "Serine Peptidase Inhibitors, Kazal Type",
"url": "https://questionsmedicales.fr/mesh/D000074162",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de serine peptidase de type Kazal",
"code": {
"@type": "MedicalCode",
"code": "D000074162",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.800.562"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Serpines",
"alternateName": "Serpins",
"url": "https://questionsmedicales.fr/mesh/D015843",
"about": {
"@type": "MedicalCondition",
"name": "Serpines",
"code": {
"@type": "MedicalCode",
"code": "D015843",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.800.675"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs trypsiques",
"alternateName": "Trypsin Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D014361",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs trypsiques",
"code": {
"@type": "MedicalCode",
"code": "D014361",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.800.900"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de serine peptidase de type Kazal",
"alternateName": "Serine Peptidase Inhibitors, Kazal Type",
"url": "https://questionsmedicales.fr/mesh/D000074162",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de serine peptidase de type Kazal",
"code": {
"@type": "MedicalCode",
"code": "D000074162",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.800.562"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Serpines",
"alternateName": "Serpins",
"url": "https://questionsmedicales.fr/mesh/D015843",
"about": {
"@type": "MedicalCondition",
"name": "Serpines",
"code": {
"@type": "MedicalCode",
"code": "D015843",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.800.675"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs trypsiques",
"alternateName": "Trypsin Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D014361",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs trypsiques",
"code": {
"@type": "MedicalCode",
"code": "D014361",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.800.900"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de protéines kinases",
"alternateName": "Protein Kinase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D047428",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de protéines kinases",
"code": {
"@type": "MedicalCode",
"code": "D047428",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.755"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs des Janus kinases",
"alternateName": "Janus Kinase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D000075242",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des Janus kinases",
"code": {
"@type": "MedicalCode",
"code": "D000075242",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.755.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de protéine-tyrosine kinase",
"alternateName": "Tyrosine Protein Kinase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D000092004",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de protéine-tyrosine kinase",
"code": {
"@type": "MedicalCode",
"code": "D000092004",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.755.875"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la synthèse protéique",
"alternateName": "Protein Synthesis Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D011500",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la synthèse protéique",
"code": {
"@type": "MedicalCode",
"code": "D011500",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.760"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la pompe à protons",
"alternateName": "Proton Pump Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D054328",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la pompe à protons",
"code": {
"@type": "MedicalCode",
"code": "D054328",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.848"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Agents découplants",
"alternateName": "Uncoupling Agents",
"url": "https://questionsmedicales.fr/mesh/D014475",
"about": {
"@type": "MedicalCondition",
"name": "Agents découplants",
"code": {
"@type": "MedicalCode",
"code": "D014475",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.936"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Antienzymes",
"alternateName": "Enzyme Inhibitors",
"code": {
"@type": "MedicalCode",
"code": "D004791",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Xiaoxi Liu",
"url": "https://questionsmedicales.fr/author/Xiaoxi%20Liu",
"affiliation": {
"@type": "Organization",
"name": "Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA."
}
},
{
"@type": "Person",
"name": "Robert S Magin",
"url": "https://questionsmedicales.fr/author/Robert%20S%20Magin",
"affiliation": {
"@type": "Organization",
"name": "Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA."
}
},
{
"@type": "Person",
"name": "Nathan J Schauer",
"url": "https://questionsmedicales.fr/author/Nathan%20J%20Schauer",
"affiliation": {
"@type": "Organization",
"name": "Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA."
}
},
{
"@type": "Person",
"name": "Sara J Buhrlage",
"url": "https://questionsmedicales.fr/author/Sara%20J%20Buhrlage",
"affiliation": {
"@type": "Organization",
"name": "Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA. saraj_buhrlage@dfci.harvard.edu."
}
},
{
"@type": "Person",
"name": "R Gentry Wilkerson",
"url": "https://questionsmedicales.fr/author/R%20Gentry%20Wilkerson",
"affiliation": {
"@type": "Organization",
"name": "Department of Emergency Medicine, University of Maryland School of Medicine, 110 South Paca Street, 6th Floor, Suite 200, Baltimore, MD 21201, USA. Electronic address: gwilkerson@som.umaryland.edu."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "The complexity of female orgasm and ejaculation.",
"datePublished": "2022-10-08",
"url": "https://questionsmedicales.fr/article/36208324",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00404-022-06810-y"
}
},
{
"@type": "ScholarlyArticle",
"name": "Does Clitoral Knowledge Translate into Orgasm? The Interplay Between Clitoral Knowledge, Gendered Sexual Scripts, and Orgasm Experience.",
"datePublished": "2022-11-21",
"url": "https://questionsmedicales.fr/article/36411727",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/0092623X.2022.2147112"
}
},
{
"@type": "ScholarlyArticle",
"name": "Development of the Italian version of the Orgasmic Perception Questionnaire (OPQ).",
"datePublished": "2023-10-24",
"url": "https://questionsmedicales.fr/article/37874816",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0288850"
}
},
{
"@type": "ScholarlyArticle",
"name": "Evaluating the Subjective Orgasm Experience Through Sexual Context, Gender, and Sexual Orientation.",
"datePublished": "2022-12-12",
"url": "https://questionsmedicales.fr/article/36508069",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10508-022-02493-3"
}
},
{
"@type": "ScholarlyArticle",
"name": "What happens to orgasmic function after surgical benign prostate hypertrophy (BPH) treatments?",
"datePublished": "2024-02-04",
"url": "https://questionsmedicales.fr/article/38717458",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.fjurol.2024.102570"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Mécanismes moléculaires de l'action pharmacologique",
"item": "https://questionsmedicales.fr/mesh/D045504"
},
{
"@type": "ListItem",
"position": 5,
"name": "Antienzymes",
"item": "https://questionsmedicales.fr/mesh/D004791"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Antienzymes - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Antienzymes",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-18",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Antienzymes",
"description": "Comment diagnostiquer une inhibition enzymatique ?\nQuels symptômes indiquent une inhibition enzymatique ?\nQuels tests sont utilisés pour détecter les antienzymes ?\nPeut-on utiliser l'imagerie pour diagnostiquer ?\nQuels marqueurs biochimiques sont associés aux antienzymes ?",
"url": "https://questionsmedicales.fr/mesh/D004791?mesh_terms=Orgasm&page=1#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Antienzymes",
"description": "Quels sont les symptômes d'une inhibition enzymatique ?\nL'inhibition enzymatique peut-elle causer des douleurs ?\nY a-t-il des symptômes spécifiques selon l'enzyme inhibée ?\nLes symptômes sont-ils toujours présents ?\nComment les symptômes évoluent-ils avec le temps ?",
"url": "https://questionsmedicales.fr/mesh/D004791?mesh_terms=Orgasm&page=1#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Antienzymes",
"description": "Comment prévenir l'inhibition enzymatique ?\nLes vaccinations peuvent-elles prévenir des inhibitions enzymatiques ?\nY a-t-il des habitudes de vie à adopter ?\nLes contrôles médicaux réguliers sont-ils importants ?\nL'éducation sur les médicaments est-elle nécessaire ?",
"url": "https://questionsmedicales.fr/mesh/D004791?mesh_terms=Orgasm&page=1#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Antienzymes",
"description": "Quels traitements existent pour l'inhibition enzymatique ?\nLes antienzymes sont-ils utilisés en chimiothérapie ?\nComment les inhibiteurs enzymatiques sont-ils administrés ?\nY a-t-il des effets secondaires aux antienzymes ?\nLes traitements sont-ils personnalisés ?",
"url": "https://questionsmedicales.fr/mesh/D004791?mesh_terms=Orgasm&page=1#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Antienzymes",
"description": "Quelles complications peuvent survenir avec l'inhibition enzymatique ?\nL'inhibition enzymatique peut-elle entraîner des maladies chroniques ?\nY a-t-il des risques de surdosage avec les antienzymes ?\nComment gérer les complications liées aux antienzymes ?\nLes complications sont-elles réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D004791?mesh_terms=Orgasm&page=1#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Antienzymes",
"description": "Quels sont les facteurs de risque d'inhibition enzymatique ?\nL'âge influence-t-il le risque d'inhibition enzymatique ?\nLes maladies auto-immunes sont-elles un facteur de risque ?\nLe mode de vie affecte-t-il le risque ?\nLes médicaments peuvent-ils être des facteurs de risque ?",
"url": "https://questionsmedicales.fr/mesh/D004791?mesh_terms=Orgasm&page=1#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une inhibition enzymatique ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et des analyses biochimiques évaluent l'activité enzymatique."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une inhibition enzymatique ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la fatigue, la douleur abdominale ou des troubles digestifs peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour détecter les antienzymes ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests d'activité enzymatique et les dosages spécifiques d'anticorps sont courants."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser l'imagerie pour diagnostiquer ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie peut aider à évaluer les organes affectés, mais n'est pas spécifique aux antienzymes."
}
},
{
"@type": "Question",
"name": "Quels marqueurs biochimiques sont associés aux antienzymes ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les niveaux d'enzymes spécifiques dans le sang peuvent indiquer une inhibition enzymatique."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une inhibition enzymatique ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent douleurs abdominales, nausées, et troubles métaboliques."
}
},
{
"@type": "Question",
"name": "L'inhibition enzymatique peut-elle causer des douleurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut entraîner des douleurs dues à des troubles digestifs ou métaboliques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques selon l'enzyme inhibée ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes varient selon l'enzyme affectée, comme la lactase ou la lipase."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils toujours présents ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, certains patients peuvent être asymptomatiques malgré une inhibition enzymatique."
}
},
{
"@type": "Question",
"name": "Comment les symptômes évoluent-ils avec le temps ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent s'aggraver si l'inhibition persiste sans traitement approprié."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'inhibition enzymatique ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et l'évitement de substances toxiques peuvent aider."
}
},
{
"@type": "Question",
"name": "Les vaccinations peuvent-elles prévenir des inhibitions enzymatiques ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines vaccinations peuvent prévenir des infections qui causent des inhibitions enzymatiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des habitudes de vie à adopter ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, éviter l'alcool et le tabac peut réduire le risque d'inhibition enzymatique."
}
},
{
"@type": "Question",
"name": "Les contrôles médicaux réguliers sont-ils importants ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des contrôles réguliers permettent de détecter précocement des problèmes enzymatiques."
}
},
{
"@type": "Question",
"name": "L'éducation sur les médicaments est-elle nécessaire ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, comprendre les effets des médicaments aide à prévenir les inhibitions enzymatiques."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour l'inhibition enzymatique ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des médicaments spécifiques et des modifications diététiques."
}
},
{
"@type": "Question",
"name": "Les antienzymes sont-ils utilisés en chimiothérapie ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains antienzymes sont utilisés pour cibler des enzymes dans les cellules cancéreuses."
}
},
{
"@type": "Question",
"name": "Comment les inhibiteurs enzymatiques sont-ils administrés ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent être administrés par voie orale, intraveineuse ou topique selon le cas."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires aux antienzymes ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des effets secondaires comme des nausées, des éruptions cutanées ou des douleurs peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le traitement est souvent adapté en fonction de la cause et de la gravité de l'inhibition."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec l'inhibition enzymatique ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des troubles métaboliques ou des maladies organiques peuvent survenir."
}
},
{
"@type": "Question",
"name": "L'inhibition enzymatique peut-elle entraîner des maladies chroniques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une inhibition prolongée peut contribuer à des maladies chroniques comme le diabète."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de surdosage avec les antienzymes ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un surdosage peut entraîner des effets indésirables graves et des complications."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées aux antienzymes ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion implique un suivi médical régulier et des ajustements de traitement."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié et rapide."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque d'inhibition enzymatique ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des maladies héréditaires et des habitudes alimentaires."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque d'inhibition enzymatique ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque augmente souvent avec l'âge en raison de la dégradation enzymatique naturelle."
}
},
{
"@type": "Question",
"name": "Les maladies auto-immunes sont-elles un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines maladies auto-immunes peuvent augmenter le risque d'inhibition enzymatique."
}
},
{
"@type": "Question",
"name": "Le mode de vie affecte-t-il le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent le risque."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils être des facteurs de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent interférer avec l'activité enzymatique et augmenter le risque."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 22/04/2025
Contenu vérifié selon les dernières recommandations médicales
2 publications dans cette catégorie
Affiliations :
Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
Publications dans "Antienzymes" :
2 publications dans cette catégorie
Affiliations :
Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
Publications dans "Antienzymes" :
2 publications dans cette catégorie
Affiliations :
Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
Publications dans "Antienzymes" :
2 publications dans cette catégorie
Affiliations :
Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA. saraj_buhrlage@dfci.harvard.edu.
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. saraj_buhrlage@dfci.harvard.edu.
Center for Emergent Drug Targets, Dana-Farber Cancer Institute, Boston, MA, USA. saraj_buhrlage@dfci.harvard.edu.
Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. saraj_buhrlage@dfci.harvard.edu.
Publications dans "Antienzymes" :
2 publications dans cette catégorie
Affiliations :
Department of Emergency Medicine, University of Maryland School of Medicine, 110 South Paca Street, 6th Floor, Suite 200, Baltimore, MD 21201, USA. Electronic address: gwilkerson@som.umaryland.edu.
Publications dans "Antienzymes" :
2 publications dans cette catégorie
Affiliations :
Department of Emergency Medicine, University of Maryland School of Medicine, 110 South Paca Street, 6th Floor, Suite 200, Baltimore, MD 21201, USA. Electronic address: https://twitter.com/critcareguys.
Publications dans "Antienzymes" :
2 publications dans cette catégorie
Affiliations :
Laboratoire de Synthèse et Physico-Chimie de Molécules d'Intérêt Biologique (SPCMIB), UMR5068, CNRS, Université Paul Sabatier Toulouse III, 31062 Toulouse, France.
Publications dans "Antienzymes" :
2 publications dans cette catégorie
Affiliations :
Department of Biology and Biotechnology "Lazzaro Spallanzani", University of Pavia, 27100 Pavia, Italy.
Publications dans "Antienzymes" :
2 publications dans cette catégorie
Affiliations :
Department of Biology and Biotechnology "Lazzaro Spallanzani", University of Pavia, 27100 Pavia, Italy.
Publications dans "Antienzymes" :
2 publications dans cette catégorie
Affiliations :
Laboratoire de Synthèse et Physico-Chimie de Molécules d'Intérêt Biologique (SPCMIB), UMR5068, CNRS, Université Paul Sabatier Toulouse III, 31062 Toulouse, France.
Publications dans "Antienzymes" :
1 publication dans cette catégorie
Affiliations :
Department of Biochemistry and Molecular Biology, Sealy Center for Structural Biology and Molecular Biophysics, The University of Texas Medical Branch, Galveston, TX, United States.
Publications dans "Antienzymes" :
1 publication dans cette catégorie
Affiliations :
Department of Biochemistry and Molecular Biology, Sealy Center for Structural Biology and Molecular Biophysics, The University of Texas Medical Branch, Galveston, TX, United States.
Publications dans "Antienzymes" :
1 publication dans cette catégorie
Affiliations :
Department of Biochemistry and Molecular Biology, Sealy Center for Structural Biology and Molecular Biophysics, The University of Texas Medical Branch, Galveston, TX, United States. Electronic address: kychoi@utmb.edu.
Publications dans "Antienzymes" :
1 publication dans cette catégorie
Affiliations :
Institute of Translational Medicine, Department of Pharmacology, School of Medicine, Yangzhou University, Yangzhou, Jiangsu, 225001, People's Republic of China.
Publications dans "Antienzymes" :
1 publication dans cette catégorie
Affiliations :
Institute of Translational Medicine, Department of Pharmacology, School of Medicine, Yangzhou University, Yangzhou, Jiangsu, 225001, People's Republic of China.
Publications dans "Antienzymes" :
1 publication dans cette catégorie
Affiliations :
Institute of Translational Medicine, Department of Pharmacology, School of Medicine, Yangzhou University, Yangzhou, Jiangsu, 225001, People's Republic of China.
Publications dans "Antienzymes" :
1 publication dans cette catégorie
Affiliations :
Institute of Translational Medicine, Department of Pharmacology, School of Medicine, Yangzhou University, Yangzhou, Jiangsu, 225001, People's Republic of China.
Publications dans "Antienzymes" :
1 publication dans cette catégorie
Affiliations :
Institute of Translational Medicine, Department of Pharmacology, School of Medicine, Yangzhou University, Yangzhou, Jiangsu, 225001, People's Republic of China.
Jiangsu Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Treatment of Senile Diseases, Yangzhou, Jiangsu, 225001, People's Republic of China.
Publications dans "Antienzymes" :
1 publication dans cette catégorie
Affiliations :
School of Pharmacy, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Publications dans "Antienzymes" :
1 publication dans cette catégorie
Affiliations :
Clinical Chemistry-Biochemistry, International Hellenic University, 57400 Thessalonik, Greece.
Publications dans "Antienzymes" :
The anatomy and physiology of the female orgasm are often neglected. The female orgasm is a normal psychophysiological function to all women, and some even can achieve ejaculation as part of the norma...
Despite some efforts to enhance clitoral knowledge to increase women's sexual pleasure, a gendered orgasm gap persists. We aimed to provide contemporary data on people's knowledge about the clitoris a...
Orgasm is a phase of the human sexual response, and the possible discrepancies between male and female ways to experience it are still not clear in the literature. There is a lack of tools to adequate...
The subjective orgasm experience (SOE) is the psychological perception of orgasm sensations and closely related to sexual health. Here, SOE was studied through the context in which it is experienced (...
The increasing number of subjects with benign prostate obstruction (BPO) has become a worldwide concern. The sexual problem after benign prostate enlargement (BPE) surgery that has received the most a...
We evaluated the prospective, multicenter clinical data of 104 patients undergoing BPE surgery who reported maintaining sexual activity from January 2016 to November 2020. The endpoint of this study w...
Orgasm function was stable, improved, and degraded in 34% (n=35), 30% (n=31), and 36% (n=38) respectively. A deterioration in orgasm was statistically significant in men who maintained quality ejacula...
To enable the patient to maintain a satisfying and healthy sex life after any BPE surgery, urologist physicians should know the prevalence of orgasmic side effects after surgical treatment to provide ...
Grade 4....
The endogenous μ-opioid receptor (MOR) system plays a key role in the mammalian reward circuit. Human and animal experiments suggest the involvement of MORs in human sexual pleasure, yet this hypothes...
To assess the reported changes in orgasm quality and function of transgender men (TM) and transgender women (TW) after commencing gender-affirming hormone therapy (GAHT)....
We queried potential changes in orgasm function before and after commencing GAHT (minimum 1 year) among 130 consecutive TW and 33 TM. We queried the following domains under a uniform condition (mastur...
Within groups by gender, TW and TM reported similar responses to our inventory before starting GAHT. After commencing GAHT, TW reported notable changes in orgasm function: increase in lead-time necess...
GAHT has the potential to positively improve orgasm quality for transgender patients undergoing gender transition. It is important to share such data with patients prospectively before treatments....
In a confidential U.S. nationally representative survey of 2,525 adults (1300 women, 1225 men), we examined participants' event-level sexual behaviors, predictors of pleasure and orgasm, and perceived...
Postpartum pelvic floor dysfunction is known to affect the quality of life of women and the methods to treat it are more complex with majority requiring training under supervision....
To compare the efficacy of sexually induced orgasm along with Kegels exercises versus Kegels exercises alone as a treatment method to enhance postpartum pelvic floor muscle strength and sexual functio...
The prospective randomized two-arm study was conducted on sexually active primiparous women who had undergone uncomplicated vaginal deliveries. Those with risk factors for female sexual dysfunction an...
Postpartum pelvic floor strength and sexual function in 2 groups of women under study....
The study period was from January 2020 to December 2020. The Group 1 had 26 participants (mean age 29.69 ± 2.2 years) and Group 2 had 29 participants (mean age 30.07 ± 2.57 years). The sexual function...
Novel method of using naturally occurring sexually induced orgasms for postpartum pelvic floor rehabilitation can revolutionize postpartum pelvic floor training in women, as it can be practiced at hom...
Use of prospective randomization and minimization of confounding factors is the strength of the study. The small sample size is the limitation of the study....
Postpartum pelvic floor muscle strength and sexual function in primiparous women who have undergone uncomplicated vaginal deliveries can be significantly improved with the addition of sexually induced...
The integrity of the neural pathways that link genital sensitive areas to the brain and the correlation with subjective sensations in transgender women with gender dysphoria after gender affirming sur...
To test with electrophysiology the integrity of the nervous paths after GAS, and to explore the relationship between genital sensitivity and self-perceived orgasmic intensity in transgender women afte...
Six patients who underwent GAS between 2016 and 2019 were enrolled in the study, and the evaluation of genital and pelvic neural pathways was performed....
Genital sensory thresholds (at clitoral, vaginal, and anal sites) investigated by Somatosensory Evoked Potentials (SEP) and the intensity of orgasm (measured by a psychometric tool, the Orgasmometer) ...
SSEPs confirmed the integrity of the large diameter, dorsal column-lemniscus pathway subserving the genital area after GAS. Perceptual Threshold (PT) values were much lower at the neoclitoris compared...
These findings could lead clinicians to a better understanding of postsurgical sexual life in transgender women in order to develop surgical techniques that could focus more on functional aspects of n...
Limitations: study very preliminary/exploratory; small number of patients; no long-term follow-up. Strengths: first assessment of sensory pelvic floor innervation in transgender women after GAS; use o...
Our evaluation showed that SSEPs is a good indicator of neural sensitivity, especially in neoclitoris, and that these measurements were consistent with the analysis of self-perceived orgasmic intensit...